Astrazeneca (AZN) Income towards Parent Company (2016 - 2026)

Astrazeneca has reported Income towards Parent Company over the past 16 years, most recently at $3.1 billion for Q1 2026.

For Q1 2026, Income towards Parent Company fell 23.33% year-over-year to $3.1 billion; the TTM value through Mar 2026 reached $12.0 billion, up 18.61%, while the annual FY2025 figure was $10.2 billion, 45.34% up from the prior year.
Income towards Parent Company for Q1 2026 was $3.1 billion at Astrazeneca, up from $2.8 billion in the prior quarter.
Over five years, Income towards Parent Company peaked at $4.0 billion in Q1 2025 and troughed at -$372.0 million in Q2 2022.
A 5-year average of $2.0 billion and a median of $1.9 billion in 2024 define the central range for Income towards Parent Company.
Biggest five-year swings in Income towards Parent Company: tumbled 131.26% in 2022 and later skyrocketed 588.71% in 2023.
Year by year, Income towards Parent Company stood at $1.7 billion in 2022, then increased by 4.03% to $1.8 billion in 2023, then decreased by 15.78% to $1.5 billion in 2024, then soared by 84.67% to $2.8 billion in 2025, then rose by 11.19% to $3.1 billion in 2026.
Business Quant data shows Income towards Parent Company for AZN at $3.1 billion in Q1 2026, $2.8 billion in Q4 2025, and $2.6 billion in Q3 2025.

Peer Comparison